Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03758989 · ClinicalTrials.gov registry record · Phase 2

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

A Phase 2 study of DLBCL, sponsored by University of Rochester.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT03758989 is a Phase 2 study of DLBCL that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 40 participants, below the 123-participant average among 14 other DLBCL trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03758989, a Phase 2 study of DLBCL, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.

Conditions Studied

DLBCL

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Vincristine
  • DRUG Prednisone
  • DRUG Rituximab Prednisone

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-05-08
Est. Completion 2027-06-01
Phase Phase 2

Sponsor

University of Rochester

636 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03758989

The ClinicalTrials.gov registry entry for NCT03758989 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 14 other DLBCL trials with a reported enrollment target (67% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with DLBCL appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT03758989 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03758989 about?

NCT03758989 is a clinical study titled "A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma". The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future ...

What is the current status of trial NCT03758989?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-05-08. Estimated completion is 2027-06-01.

What conditions does trial NCT03758989 study?

This clinical trial studies the following conditions: DLBCL.

What interventions are being tested in trial NCT03758989?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Prednisone (DRUG), Rituximab Prednisone (DRUG).

Who is sponsoring clinical trial NCT03758989?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03758989 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for DLBCL

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

DLBCL

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.